The diagnosis of cystic fibrosis.

Cystic fibrosis is an autosomal recessive disease caused by mutations of a gene located on the long arm of chromosome 7.1 The gene product is the 1480-amino-acid cystic fibrosis transmembrane conductance regulator (CFTR), a protein that normally regulates and participates in the transport of electrolytes across epithelial-cell membranes and probably across intracellular membranes as well.2 Recent advances in genetics and molecular biology have led to the introduction of new tests for cystic fibrosis and to a reconsideration of the spectrum of the disease. Although the primary manifestations are presumably related, at least in part, to abnormal transport of electrolytes, the . . .

[1]  T. Boat,et al.  OBSTRUCTIVE AZOOSPERMIA AS A DIAGNOSTIC CRITERION FOR THE CYSTIC FIBROSIS SYNDROME , 1982, The Lancet.

[2]  P. Hu,et al.  A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. , 1995, The New England journal of medicine.

[3]  David Handelsman,et al.  Young's syndrome. Obstructive azoospermia and chronic sinopulmonary infections. , 1984, The New England journal of medicine.

[4]  Q. Al-Awqati,et al.  Defective acidification of the biosynthetic pathway in cystic fibrosis , 1993, Journal of Cell Science.

[5]  P. di Sant'Agnese,et al.  Low sweat electrolytes in a patient with cystic fibrosis. , 1980, The American journal of medicine.

[6]  D. Riches,et al.  Early pulmonary inflammation in infants with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[7]  M. Knowles,et al.  In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. , 1995, Human gene therapy.

[8]  G. Loughlin,et al.  Clinical application of transepithelial potential difference measurements in cystic fibrosis. , 1987, The Journal of pediatrics.

[9]  M. Knowles,et al.  Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. , 1981, The New England journal of medicine.

[10]  R. Stern,et al.  Treatment and Prognosis of Symptomatic Gallbladder Disease in Patients with Cystic Fibrosis , 1986, Journal of pediatric gastroenterology and nutrition.

[11]  H. Joos,et al.  PARANASAL SINUSES IN CYSTIC FIBROSIS. INCIDENCE OF ROENTGEN ABNORMALITIES. , 1964, American journal of diseases of children.

[12]  J. Carlin,et al.  Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis , 1996, Pediatric pulmonology.

[13]  F. Accurso,et al.  Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. , 1991, The Journal of pediatrics.

[14]  M. Welsh,et al.  Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. , 1995, EMBO Journal.

[15]  C. Arvanitakis,et al.  Diagnosis of exocrine pancreatic insufficiency in cystic fibrosis by the synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid. , 1978, The Journal of pediatrics.

[16]  D. Geddes,et al.  No added benefit from nebulized amiloride in patients with cystic fibrosis. , 1993, The European respiratory journal.

[17]  M. Drumm,et al.  3849+10 kb C→T mutation and disease severity in cystic fibrosis , 1995, The Lancet.

[18]  P. Lankisch.  Exocrine pancreatic function tests. , 1982, Gut.

[19]  H. Shwachman,et al.  Recurrent acute pancreatitis in patients with cystic fibrosis with normal pancreatic enzymes. , 1975, Pediatrics.

[20]  P. Phelan,et al.  Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis , 1995, BMJ.

[21]  J C Olsen,et al.  A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. , 1994, The New England journal of medicine.

[22]  J. Zieleński,et al.  Cystic fibrosis: genotypic and phenotypic variations. , 1995, Annual review of genetics.

[23]  R. Gibson,et al.  Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. , 1991, The American review of respiratory disease.

[24]  M. Knowles,et al.  Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. , 1996, American journal of respiratory and critical care medicine.

[25]  C. Hunt,et al.  Increased sweat chloride levels associated with prostaglandin E1 infusion. , 1985, The Journal of pediatrics.

[26]  M. King,et al.  Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. , 1990, The American review of respiratory disease.

[27]  M. King,et al.  A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. , 1990, The New England journal of medicine.

[28]  M. Konstan,et al.  Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. , 1994, American journal of respiratory and critical care medicine.

[29]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.

[30]  L. Cantley,et al.  Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. , 1986, The Journal of clinical investigation.

[31]  M Claustres,et al.  Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. , 1995, The New England journal of medicine.

[32]  G. Barbero,et al.  Stool trypsin and chymotrypsin. Value in the diagnosis of pancreatic insufficiency in cystic fibrosis. , 1966, American journal of diseases of children.